Register Now: Beyond EDC: Designing a Connected Data Strategy for Predictive Clinical Development
Commentary|Videos|March 23, 2026

How AI and Wearables Together Could Transform Clinical Oversight

In this video interview, Mohammed Saeed, MD, PhD, chief medical officer of Solera Health, explores how AI models capable of analyzing continuous wearable data streams alongside broader patient information could detect subtle warning signs of deterioration that no clinician could identify alone.

Full interview summary

In a recent video interview with Applied Clinical Trials, Mohammed Saeed, MD, PhD, chief medical officer of Solera Health, discussed how wearable devices and continuous remote monitoring are giving clinicians unprecedented visibility into patient health outside the clinic, enabling earlier interventions and more proactive care management. He opened by emphasizing that wearable data captures something fundamentally unavailable from traditional clinical encounters: a real-world picture of how a patient's health holds up to everyday stresses. That unique insight, he noted, is becoming increasingly central to identifying patients who need earlier support before their conditions worsen.

Saeed went on to explain how continuous remote monitoring is shifting care delivery from reactive to proactive, allowing care teams to spot early warning signs of deterioration and make timely adjustments well before a patient reaches the emergency room. Whether that means a simple medication change over the phone or a more urgent escalation, the ability to intervene early is, in his view, the core value proposition of remote monitoring.

He was equally candid about the obstacles that remain, pointing to information overload as one of the most pressing operational challenges. With wearables generating continuous, high-velocity data on top of already overwhelming EMR workloads, providers face a growing risk of alert fatigue. When false positives become routine, he warned, clinicians can become dangerously desensitized to alarms that genuinely matter.

Saeed also addressed the critical role of FDA clearance in establishing the provider trust necessary for wearables to become a genuine part of clinical care, and stressed that reimbursement models must evolve to reflect the real time providers invest in reviewing remote monitoring data. He closed with a forward-looking perspective on how AI could parse massive, multi-source data streams and detect patterns too subtle for human observation, including changes in speaking patterns as early predictors of heart failure, potentially reshaping clinical oversight across a wide range of conditions.


Related to this article

What Expanding AI Ecosystems Mean for Sponsor Complexity and Oversight
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Where AI Governance in Clinical Development Falls Short
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, identifies three recurring failure modes in AI governance frameworks—and explains why responsible AI must be an ongoing operating discipline, not a one-time approval gate.
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
What Needs to Happen Beyond the Clinical Trial Modernization Act
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.